Dyslipidemia is a metabolic disorder characterized by abnormal levels of circulating lipids, including elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, or reduced high-density lipoprotein cholesterol (HDL-C). These abnormalities contribute to atherosclerotic cardiovascular disease and are commonly associated with obesity, insulin resistance, unhealthy dietary patterns, and sedentary lifestyles. Ayurveda offers a traditional framework for understanding metabolic disturbances through concepts such as Agni (digestive and metabolic capacity), Ama (incompletely processed metabolic products), and Meda dhatu (adipose and lipid-related tissue).
Trikatu churna, a classical formulation comprising three pungent herbs, is traditionally used to support digestion and metabolism. Its potential role in lipid regulation is now being investigated through contemporary pharmacological and clinical research.
Composition and Ayurvedic properties
Trikatu churna consists of dried fruits of Piper nigrum (black pepper), Piper longum (long pepper), and the rhizome of Zingiber officinale (ginger), generally combined in equal proportions (1:1:1). In Ayurvedic practice, its pungent taste (Katu rasa), heating potency (Ushna virya), and traditional Deepana and Pachana properties are associated with stimulating digestive function and supporting metabolic processes.1 The formulation is also traditionally described as Kapha-reducing and relevant to the management of Meda-associated disturbances. These concepts provide a rationale for investigating Trikatu in metabolic conditions; however, they should not be interpreted as direct equivalents of modern biochemical pathways or as proof of clinical lipid-lowering efficacy.
Ayurvedic rationale for lipid metabolism
From an Ayurvedic perspective, impaired Agni and the accumulation of Ama may contribute to disturbances in tissue nourishment and Meda dhatu metabolism. Trikatu's traditional Deepana–Pachana actions are considered relevant to this framework because they support digestive processing and may help address Kapha- and Meda-associated imbalance. This provides a traditional rationale for studying the formulation in conditions resembling aspects of dyslipidemia and metabolic dysfunction. Nevertheless, Ayurvedic concepts of Ama and Meda dhatu do not correspond precisely to circulating LDL-C, triglycerides, or other measurable lipid fractions. Clinical assessment therefore requires validated biochemical investigations alongside the traditional framework.
Potential metabolic mechanisms
Modern pharmacological studies suggest several pathways through which Trikatu's constituents may influence lipid metabolism. Piperine, an alkaloid found in black pepper and long pepper, has demonstrated lipid-modulating effects in experimental models. A study in high-fat-diet-fed mice reported reductions in plasma triglycerides, total cholesterol, and LDL-C following piperine administration, alongside changes in hepatic scavenger receptor B1 and intestinal ABCG8 transporter expression. These findings suggest possible effects on cholesterol transport and handling, although they cannot establish the same effects in humans receiving Trikatu churna.
Ginger, another constituent, contains bioactive compounds such as gingerols and shogaols that have been investigated for antioxidant, anti-inflammatory, and metabolic effects. Experimental findings involving ginger and piperine support further investigation into lipid handling, hepatic lipid accumulation, and metabolic regulation. However, findings from isolated compounds, extracts, or animal models should not be directly extrapolated to the complete Trikatu formulation. The dose, preparation, bioavailability, and interactions among ingredients may influence its overall activity.
Emerging clinical evidence
A significant recent development is a randomized, double-blind, placebo-controlled trial protocol to evaluate Trikatu as an adjunct to standard statin therapy in adults with dyslipidemia. The planned study includes 170 participants and assesses changes in LDL-C, total cholesterol, HDL-C, triglycerides, glycemic markers, inflammatory biomarkers, and gut microbiota. The investigators propose that Trikatu may influence the gut–lipid axis, providing a potential avenue for investigating its metabolic actions.
Another prospective, single-centred, randomized, double-blind, placebo-controlled clinical trial involving 120 participants aged 30–60 years with dyslipidemia, including borderline cases with low ASCVD risk and BMI between 18.5 and 29.9 kg/m² revealed that ‘Trikatu’ can increase secretion of digestive juices which enhances the functions of enzymes in small intestine and thereby improves absorption, removes deposition of lipids by clearing blocked Srotas’s (channels carrying nutrients) due to the presence of chemical component-Piperine.2
Safety and clinical considerations
Trikatu's pungent and heating properties warrant appropriate clinical consideration, particularly in individuals susceptible to gastric irritation or acid-related symptoms.3 Piperine may also affect the absorption or metabolism of certain medicines, making assessment of potential herb–drug interactions important. The formulation should be used cautiously in pregnancy and in people with relevant gastrointestinal conditions or other contraindications. Quality-controlled products and professional guidance are essential, especially for individuals taking lipid-lowering or other long-term medication. Trikatu should not replace prescribed statins, dietary modification, physical activity, or routine lipid monitoring.
Conclusion
Trikatu churna presents a traditional Ayurvedic rationale for metabolic support through its Deepana–Pachana properties and its proposed relevance to Kapha and Meda dhatu disturbances. Experimental research on piperine suggests possible effects on cholesterol transport and lipid metabolism, while a recent clinical trial protocol signals growing interest in evaluating the complete formulation in dyslipidemia. Nevertheless, robust clinical evidence demonstrating its lipid-lowering efficacy and long-term safety remains necessary. Its potential role should therefore be considered investigational and complementary to evidence-based dyslipidemia management.
References:
- Sharma H, Chincholikar MB, Mahajon B, Lale SK, Narasimhaji CV, Singh R. Scientific appraisal of Trikatu churna for its advancement and clinical practice. International Journal of Ayurveda Research. 2026 Apr 1;7(2):210-21. https://www.ovid.com/jnls/ijar/fulltext/10.4103/ijar.ijar_273_24~scientific-appraisal-of-trikatu-churna-for-its-advancement?an=01437112-202604000-00004
- Jameela S, Bm B, Khanduri S, CHANDRASHEKARA B, RAO GK, Singhal R, Sharma BS, Bhat S, Narayanam S, Acharya R. Efficacy and Safety of Ayurveda Formulation ‘Trikatu’in Dyslipidemia: A Study Protocol for a Prospective Randomized Double Blind Placebo Controlled Trial. Jmir. https://www.researchgate.net/profile/Bhavya-Bm-2/publication/398571323_Efficacy_and_Safety_of_Ayurveda_Formulation_'Trikatu'_in_Dyslipidemia_A_Study_Protocol_for_a_Prospective_Randomized_Double_Blind_Placebo_Controlled_Trial/links/693a89bc7e61d05b530de22d/Efficacy-and-Safety-of-Ayurveda-Formulation-Trikatu-in-Dyslipidemia-A-Study-Protocol-for-a-Prospective-Randomized-Double-Blind-Placebo-Controlled-Trial.pdf
- Murunikkara V, Rasool M. Trikatu, a herbal compound that suppresses monosodium urate crystal-induced inflammation in rats, an experimental model for acute gouty arthritis. Cell Biochem Funct. 2014;32(1):106-114. doi:10.1002/cbf.2979. https://pubmed.ncbi.nlm.nih.gov/23674350/